Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

A recent study published in Neurology explored whether high doses of nicotinamide, a derivative of vitamin B3, could reduce a ...

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder hallmarked with ... Therefore, targeting neurite outgrowth and neuronal protection probably be a new strategy for the treatment of ...

Its primary role is to manage your body’s natural sleep-wake cycle. People with low melatonin may have trouble falling or staying asleep. Alzheimer’s disease is a progressive neurodegenerative ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

Since it has been nearly impossible to suggest a holistic solution for the disease, several alternative diagnostic and treatment procedures have been presented during the last years, without ...

Note: Alzheimer’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Troculeucel is under clinical development by NKGen Biotech and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...